5 Questions: Progress in peanut-allergy immunotherapy
Stanford School of Medicine News Dec 02, 2018
Any parent of a child with a severe peanut allergy knows the peril of a PB&J. For those with the condition, just sitting next to someone eating peanut butter can trigger a life-threatening reaction.
Now, scientists have established the validity of what could become the first oral anti-peanut-allergy drug. Stanford was one of 66 sites to participate in a phase 3 clinical trial of the therapy. The results were published November 22 in The New England Journal of Medicine. Sharon Chinthrajah,...
To read this article Sign up / Login for free
- Stay on top of policy changes & daily news that matter to you as a healthcare professional
- Update yourself with quick summaries from reputed journals in your specialty
- Earn from paid surveys and influence new developments in healthcare
- Participate in daily quizzes to improve skills and compete with peers
- Save yourself time, as we bring you these and more useful features all at one place!
You get a FREE lifetime membership, with a simple one-time sign up process!